B-Cell Chronic Lymphocytic Leukemia – Pipeline Review, 2019

Leukemia is a type of blood cancer. Leukemia initiates when healthy blood cells change and grow out of control. Chronic lymphocytic leukemia (CLL) is a cancer of the lymphocytes. The chronic lymphocytic leukemia (CLL) is categorized based on the type of cells affected such as B cells or T cells. Generally, no symptoms can be identified at an earlier stage. Non-painful lymph nodes swelling, fever or weight loss, enlargement of the spleen and a low red blood cells (anemia) are some of the symptoms seen at a later stage of the Chronic lymphocytic leukemia (CLL). According to, American Society of Clinical Oncology (ASCO) more than 95% people with chronic lymphocytic leukemia (CLL) were suffering from B- cell chronic lymphocytic leukemia (CLL).

Current treatment for B-cell chronic lymphocytic leukemia includes radiation therapy, chemotherapy, surgery, and targeted therapy. Chemotherapy with stem cell transplant and immunotherapy are some of the treatments being studied under the pipeline. Recently, in May 2019, AbbVie Inc., received U.S. Food and Drug Administration (FDA) approval for VENCLEXTA in combination with obinutuzumab for previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Research Institutes and pharmaceutical companies are focusing on studying and developing new methods for the treatment of B-cell chronic lymphocytic leukemia. For instance; PCI-32765 (Ibrutinib) which is being studied by the Janssen Research & Development, LLC, is currently in phase-3 clinical trials for the study of the collect long-term safety and efficacy data for participants treated with PCI-32765 towards chronic lymphocytic leukemia and other disease conditions.

Currently, more than 50% of the pipeline candidates for B-cell chronic lymphocytic leukemia are in phase 1 and phase 2. Majority of the studies have been sponsored by pharmaceutical companies.

REPORT DESCRIPTION

The report on ‘B-Cell Chronic Lymphocytic Leukemia – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for B-Cell Chronic Lymphocytic Leukemia. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for B-Cell Chronic Lymphocytic Leukemia.

The report on ‘B-Cell Chronic Lymphocytic Leukemia – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

•  Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for B-cell Chronic Lymphocytic Leukemia
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for B-Cell Chronic Lymphocytic Leukemia
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary